QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global leader of innovative in vitro diagnostics, announces it has completed the acquisition of LEX Diagnostics (“LEX”) for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration (“FDA”) 510(k) clearance and CLIA waiver in February 2026. The LEX VELO […]
QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics Read More »
